1. 2356 Phase I dose-escalation study of nintedanib in Japanese patients with advanced hepatocellular carcinoma (HCC) and mild or moderate liver impairment. (September 2015) Authors: Ikeda, M.; Otsuka, T.; Ueno, H.; Mitsunaga, S.; Sugimoto, R.; Muro, K.; Saito, I.; Sasaki, T.; Inoue, K.; Loembe, A.B.; Okusaka, T. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S454 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗